drugset / Trial / NCT06556368
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Timeline
- Start
- 2024-08-23
- Primary completion
- 2026-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Tabirafusp tedromer | Unknown | 5 mg | Intravitreal |
| Subject | Tarcocimab tedromer | Protein / enzyme biologic | 5 mg | Intravitreal |